News Archives - Amylon

Amylon appoints Art Levin to supervisory board; expands scientific advisory board

Jan 30, 2019 | News, Uncategorized

Amylon appoints Art Levin to supervisory board; expands scientific advisory board Cambridge, Massachusetts, January 17th 2019 Amylon Therapeutics, a biotechnology company using RNA modulation to target neurological disorders, announces the appointment of Art Levin as...

Dan Curtis joins Amylon Therapeutics as Chief Development Officer

Jan 10, 2019 | News

Dan Curtis joins Amylon Therapeutics as Chief Development Officer Cambridge, Massachusetts, 26 June 2018 Amylon Therapeutics, a biotechnology company using an ultragenetics approach towards neurological disorders, announces the appointment of Daniel Curtis PhD as its...

Amylon Therapeutics and Alcyone Lifesciences enter into partnership on drug-device combo to treat HCHWA-D

Jan 10, 2019 | News

Amylon Therapeutics and Alcyone Lifesciences enter into partnership on drug-device combo to treat HCHWA-D Cambridge, Massachusetts, April 5, 2018 Amylon Therapeutics, a biotechnology company using an ultra-genetics approach towards neurological disorders, and Alcyone...

Dr. Bo Jesper Hansen joins supervisory board Amylon Therapeutics

Jan 10, 2019 | News

Dr. Bo Jesper Hansen joins supervisory board Amylon Therapeutics LEIDEN, The Netherlands, February 21st 2018, Amylon Therapeutics, a biotechnology company using an ultra-genetic approach towards neurological disorders, announces the appointment of Bo Jesper Hansen MD,...

Amylon Therapeutics Targeting central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe® Berlin

Jan 10, 2019 | News, Uncategorized

Amylon Therapeutics Targeting central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe® Berlin Eight short-listed life sciences startups pitched to expert panel of judges at fourth Startup Slam competition at BIO-Europe® 2017 Startup Slam sponsor...

ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics

Jan 10, 2019 | News

ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, with seed funding from a group of institutional and private investors. As part of...

« Older Entries

Amylon appoints Art Levin to supervisory board; expands scientific advisory board

Dan Curtis joins Amylon Therapeutics as Chief Development Officer

Amylon Therapeutics and Alcyone Lifesciences enter into partnership on drug-device combo to treat HCHWA-D

Dr. Bo Jesper Hansen joins supervisory board Amylon Therapeutics

Amylon Therapeutics Targeting central Nervous System Disorders Wins Startup Slam Competition at BIO-Europe® Berlin

ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics

Recent Posts

Recent Comments

Archives

Categories

Meta